A first-line biologic treatment for metastatic colorectal cancer (mCRC) is still controversial. We, therefore, performed a meta-analysis to determine the efficacy of first-line cetuximab versus bevacizumab for RAS and BRAF wild-type mCRC. | First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer A systematic review and meta-analysis